An observational study in Skeletal Dysplasia, sponsored by University of Bath. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-10.
Sponsored by University of Bath · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Mucopolysaccharidosis IV with a site in United Kingdom — 6 open to participants now, 7 under way, 1 of them phase 3. Mucopolysaccharidosis IV · United Kingdom.
Among the 22 studies in Mucopolysaccharidosis IV with a site in United Kingdom, this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 16th registered.
101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.
Browse Mucopolysaccharidosis IV studies →6 of the 22 studies in Mucopolysaccharidosis IV with a site in United Kingdom are open now. Recruiting first, the newest first:
QED Therapeutics, a BridgeBio company · Sites in United Kingdom, United States, Australia and 4 more countries
Ages 0 yrs–32 mo
University of Nottingham · Sites in United Kingdom
Ages 18–65 · Healthy volunteers
QED Therapeutics, a BridgeBio company · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 30 mo–16 yrs
QED Therapeutics, a BridgeBio company · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 3–18
QED Therapeutics, a BridgeBio company · Sites in United Kingdom, United States, Australia and 7 more countries
Ages 3–18
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 4
First in 2008; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 102 is close to the median of 100 across 41 observational studies indexed under Mucopolysaccharidosis IV.
Median enrollment 39 across the 16 interventional studies, 211 across the 6 observational. Of the 14 that completed or were terminated, 7 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 22 have an industry lead sponsor. The 6 most frequent:
University of Bath is the lead sponsor of 94 studies on the registry; 20 are open to participants now.
University of Bath has 1 study filed under Mucopolysaccharidosis IV — fewer than ten, so there is no comparison to draw.
1 of the studies in Mucopolysaccharidosis IV with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Mucopolysaccharidosis IV with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Researchers at the University of Bath are investigating the metabolism of individuals with extreme body size, including those with skeletal dysplasia (commonly known as dwarfism), to manage health risks such as heart disease. By better understanding how body size could change how the body processes food, or how being bigger or smaller may influence eating habits, healthy living guidelines to tackle issues such as obesity and overweight in these populations can be improved. With help from expertise in the psychology field, this research will also investigate whether the mental health of these individuals has been affected by their size. On the whole, this study will involve one 24-hour visit to a research laboratory at the University of Bath, followed by a 2-week monitoring period to capture 'normal' physical activity and eating routines.
After signing informed consent to take part in the study, participants will be asked to complete a health entry criteria questionnaire, including a physical activity readiness questionnaire and Eating Disorder Examination Questionnaire, to confirm eligibility. Participants will also be required to complete a health questionnaire for administration of anaesthetic as part of the biopsy procedure. Individuals who are very small or very big (without skeletal dysplasia) will be asked to attend the laboratory for a pre-trial screening as an additional eligibility criterion. This will involve measuring height, body mass, and standing on a specialised scale (bioelectrical impedance scale) which estimates how much muscle and fat someone has. If it is suspected that the participant meets the stated fat-free mass criteria, a complete a full body Dual Energy X-ray Absorptiometry (DEXA) scan to assess body composition more accurately will be completed. This involves lying flat on a bed for \~7 minutes and resting whilst the scan takes place. The research team will then inform the participant after analysing the scan results if they are eligible and can continue with the study.
All participants deemed eligible who are able and willing to take part will be invited to attend the University of Bath Human Physiology Laboratory for the full trial.
On day 1, prior to attending the University of Bath participants will be asked to eat a standardised diet of a cereal breakfast, and a supermarket purchased sandwich, drink and snack meal deal for lunch, with self-selected quantities. Participants will ideally be fasted for 4-5 hours before arrival (\~17:00).
Upon arrive at the University, individuals with skeletal dysplasia will also be asked to complete the health entry criteria questionnaire and physical activity readiness questionnaire to ensure eligibility. It is important that participants let the researchers know of any medical conditions or any change in circumstance since signing up. All information is strictly confidential.
The research team will first take measurements of height, body mass, waist and hip circumference, abdomen diameter (distance from your front to back), sitting height and blood pressure. Early into the visit, participants will also be briefed on collecting urine into provided containers. Individuals with skeletal dysplasia will then have a Dual Energy X-ray Absorptiometry (DEXA) scan to assess body composition. All participants will also have a Peripheral Quantitative Computed Tomography (pQCT) scan which involves placing one leg into a round scanner to assess the tissues in your leg e.g., bone, muscle and fat (as if the image were a slice). The scan requires you to keep your leg still for \~10 minutes.
Participants will then be asked to rest in a bed and relax. In a seated position, participants will complete a lung function test at rest which requires blowing into a specialised device through a mouthpiece. Following this, after lying down and being briefed on the procedure, a trained member of staff will take a fat tissue biopsy from the abdomen to analyse genes and proteins in the cells. The fat biopsy involves inserting a needle with suction just below the skin to extract the cells and will be performed under local anaesthetic. This procedure may cause a bruise for up to 7 days. Following on from this, a muscle biopsy will be taken from the quadriceps (large muscle on the front of the thigh) to again measure genes and proteins as well as signalling pathways involved in our metabolism. The needle is inserted just inside the muscle and 2/3 snips of tissue are collected. The research team will provide information and equipment for aftercare of the biopsy sites to prevent infection after participants leave the laboratory.
Participants will then be provided with a hot meal for dinner. This will be a standard portion of Sainsbury's Love Your Veg! Lentil Cottage Pie (400 g, serves 1). Prior to turning the lights out at 22:00, participants will be fitted with sleep monitoring kit known as polysomnography. The equipment includes an abdominal and chest pressure sensing band, a nasal cannula and some sticky sensors placed directly on the skin.
On the morning of day 2, a researcher will wake the participant at 07:00. Using a mouthpiece (alike to a snorkel) and nose clip, expired air at rest will be collected for 20 minutes to calculate how much energy is burnt at rest. Participants will also be asked to give a breath sample into a small glass tube through a straw (this is related to a tracer method explained below). Body mass will be measured again after the participant has an opportunity to use the bathroom.
Once settled back in bed, a trained member of staff will insert a cannula (small plastic tube) into a vein on the back of the participant's hand or forearm. This will stay in place for the remainder of the day and allows repeated blood samples to be taken throughout the following tests. For participants with skeletal dysplasia, the genetic material found in cells will be taken out of the first blood sample and later analysed to confirm a correct diagnosis of achondroplasia. Participants will be asked to place the hand in a warm box set at 55°C which helps blood flow and makes taking samples easier for the research team. All participants will then be asked to complete a series of appetite questions, a portion selection task, and blood pressure will be taken.
When the hand is warm and initial appetite tasks are completed, participants will be provided with a sugary drink and asked to finish it within 5 minutes. The drink will also contain a sugar tracer which is stable and safe-to-consume. This allows the research team to assess how the drink is being processed by the body in real time. For a few individuals from each 'subgroup' (achondroplasia, skeletal dysplasia, extremely large body size, and extremely small body size), a different tracer called acetate will be added to the drink which will help with some calculations of how the body processes the sugar. Blood samples (10 mL) will be drawn from the cannula every 15 minutes for the first hour, and 30 minutes for the next two hours. At these same intervals, the participant will be asked to blow into a small tube using a straw to assess the appearance of the tracer on the breath (an indicator of how much sugar is being burnt from the drink, as opposed to the body's sugar stores, hence the need for a baseline sample). Participants will also be asked to complete the appetite questions and portion selection task whenever a blood sample is drawn. At 60, 120 and 180 minutes, a one 5-minute sample of air will be collected just as upon waking, and blood pressure will be measured on the hour. In between samples the participant may also complete a series of questionnaires regarding mental health (optional).
At 11:00, participants will be presented with another appetite task and then a lunch meal (pesto pasta with cheese, and a glass of orange juice) to consume within 20-minutes. A few additional appetite questions will be asked pre- and post- meal consumption. The following 3 hours will be similar to before, with regular appetite scales to complete, and blood samples drawn every 15 minutes for the first hour, and 30 minutes for the next two hours. At 60, 120 and 180 minutes, one 5-minute breath sample and a smaller tracer breath sample through the straw will be collected, and blood pressure recorded.
Participants will then be asked to complete a short treadmill test to calibrate the activity monitor by wearing a heart rate monitor on a chest strap whilst walking. Five 3-minute incremental stages will be calculated based on the participants 'normal' self-selected walking speed. During the final minute of each stage, a one-minute breath sample will be collected and heart rate recorded. A breath sample into a tracer collection tube will also be obtained at the end of each exercise stage. Whilst on the treadmill, participants will be asked to describe how difficult the exercise stages feel. If the fastest speed has not exceeded 'hard' exercise, the researcher will ask if the participant feels able to complete a final stage at a higher intensity (not exceeding a rating of perceived exertion of 15) to assist calibration of the activity monitor. Within 30 seconds of finishing on the treadmill one final blood sample will be drawn from the cannula before removing it.
On leaving the lab, participants will be provided with an activity monitor, a motion watch, a food diary (either on a mobile app or paper copy), and food and body weight scales. A small device to continuously measure blood sugar levels will also be fitted to the back of the arm. The device is inserted with a very small needle which is then removed, leaving only the patch with a small probe in the arm. The research team will instruct participants on how to wear the activity monitor on the chest and ask that participant wear this at all times other than when swimming or bathing, and record food intake for 14-days. During this time, participants will be asked to weigh themselves first thing in the morning and last thing at night, as well as recording sleep times and quality.
Individuals with extreme body size or proportions.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Any individual with a form of skeletal dysplasia, or extremely small or large body size.
Glucose incremental area under the curve during the oral glucose tolerance test
Difference in blood glucose incremental area under the curve between individuals with skeletal dysplasia, and extremely small and large body size.
Time frame: 3 hours
Fasted blood glucose concentration
Time frame: Baseline
Fasted blood insulin concentration
Time frame: Baseline
Insulin response to oral glucose tolerance test
Incremental area under the curve of blood insulin after oral glucose tolerance test
Time frame: 3 hours
C-Peptide response to oral glucose tolerance test
Incremental area under the curve of blood C-Peptide after oral glucose tolerance test
Time frame: 3 hours
Regulatory hormone response to oral glucose tolerance test
Incremental area under the curve of regulatory hormones e.g. ghrelin after oral glucose tolerance test
Time frame: 3 hours
Glycaemic response to mixed meal tolerance test
Incremental area under the curve of blood glucose after mixed meal tolerance test
Time frame: 3 hours
Insulin response to mixed meal tolerance test
Incremental area under the curve of blood insulin after mixed meal tolerance test
Time frame: 3 hours
C-Peptide response to mixed meal tolerance test
Incremental area under the curve of blood C-Peptide after mixed meal tolerance test
Time frame: 3 hours
Regulatory hormone response to mixed meal tolerance test
Incremental area under the curve of regulatory hormones e.g. ghrelin after mixed meal tolerance test
Time frame: 3 hours
Resting metabolic rate
Time frame: Baseline
Substrate oxidation during oral glucose tolerance test
Total fat and carbohydrate oxidation
Time frame: 3 hours
Substrate oxidation during mixed meal tolerance test
Total fat and carbohydrate oxidation
Time frame: 3 hours
Exogenous carbohydrate oxidation
Time course for whole-body exogenous carbohydrate using stable isotope methodology
Time frame: 7 hours
Fasting muscle glycogen concentration
Difference between individuals with skeletal dysplasia, extremely small and large body morphology.
Time frame: Baseline
Non-oxidative glucose disposal
Difference in exogenous carbohydrate consumption and exogenous carbohydrate oxidation
Time frame: 7 hours
Continuous interstitial glucose concentration
Time frame: 10 days
Adipose tissue markers of insulin signalling
Time frame: Baseline
Adipose tissue markers of glucose metabolism
Time frame: Baseline
Skeletal muscle markers of insulin signalling
Time frame: Baseline
Skeletal muscle markers of glucose metabolism
Time frame: Baseline
Fasted concentration of systemic adipokines (e.g., adiponectin, resistin, leptin etc.)
Time frame: Baseline
Height
Metres
Time frame: Baseline
Body mass
Kilograms
Time frame: Baseline
Change in body mass over 14 days of free-living monitoring
Kilograms
Time frame: 14 days
Waist:Hip ratio
Time frame: Baseline
Sagittal abdominal diameter
Centimeters
Time frame: Baseline
Blood pressure
mmHg
Time frame: 6 hours
Intracellular markers and signalling pathways related to carbohydrate metabolism in adipose tissue
Comparing adipose tissue between skeletal dysplasia, extremely small and large groups
Time frame: Baseline
Intracellular markers and signalling pathways related to carbohydrate metabolism in skeletal muscle
Comparing muscle tissue between skeletal dysplasia, extremely small and large groups
Time frame: Baseline
Full blood lipid profile
Blood analysed and compared between skeletal dysplasia, extremely small and large groups
Time frame: 7 hours
Fasted markers of chronic low-grade inflammation
Blood analysed and compared between skeletal dysplasia, extremely small and large groups
Time frame: Baseline
FGFR protein expression and signalling pathway exploration
Muscle tissue analysed and compared between skeletal dysplasia, extremely small and large groups
Time frame: Baseline
24-hour protein oxidation
Grams per minute
Time frame: 24 hours
Genotype- FGFR3 mutation (skeletal dysplasia group only)
Assessed from buffy coat layer
Time frame: Baseline
Panel of female sex hormones
To verify menstrual cycle phase
Time frame: Baseline
DEXA bone mineral density
Time frame: Baseline
DEXA fat mass
Time frame: Baseline
DEXA fat-free mass
Time frame: Baseline
pQCT - muscle cross-sectional area
Time frame: Baseline
pQCT - tissue density
Time frame: Baseline
pQCT - bone geometry
Time frame: Baseline
Assessment of eating behaviour
The Three Factor Eating Questionnaire
Time frame: Baseline
Visual analogue scale appetite ratings
Time frame: 6 hours
Portion selection task
Time frame: 6 hours
Polysomnography profile
Time frame: Baseline
Daily self-reported energy intake during free-living monitoring
Daily self-reported energy intake using Nutritics Libro Application
Time frame: 14 days
Daily free-living physical activity energy expenditure
Daily free-living physical activity measured by Actiheart monitor
Time frame: 14 days
Free-living sleep quality
Time frame: 14 days
Free-living sleep duration
Time frame: 14 days
Free-living light exposure
Time frame: 14 days
Diet induced thermogenesis
Calculated from self-reported energy intake
Time frame: 14 days
Heart rate during exercise
Beats per minute
Time frame: 15 minutes
Rate of perceived exertion during exercise
BORG scale
Time frame: 15 minutes
Energy expenditure during exercise
Substrate oxidation during walking exercise
Time frame: 15 mins
Mental health assessment
Validated questionnaires
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Sep 2025, 27 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Bath